| 摘要 |
<p>The minimum activity-exhibiting site of substance P has now been found and the action of a compound consisting of the units constituting the minimum site on the ophthalmic region has been elucidated, on the basis of which the following ophthalmic drug compositions containing the above compound as the active ingredient are provided: an ophthalmic drug composition (particularly corneal disease remedy) containing as the active ingredient Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof; and a corneal disease remedy (particularly elongation accelerator for corneal epithelium) containing as the active ingredients Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof and insulin-like growth factor-I. These preparations preferably take the dosage form of eye drops.</p> |
